Novel Pharmacological Approaches to Neurological Diseases: A Review of Recent Clinical Breakthroughs
Novel Drugs and Neurological Diseases
Abstract views: 77
/ 
PDF downloads: 41
DOI:
https://doi.org/10.5281/zenodo.17444432Keywords:
Neurology, Pharmacotherapy, Alzheimer’s Disease, Parkinson’s Disease, Multiple SclerosisAbstract
Neurological diseases present significant global health challenges due to their high prevalence, substantial disability burden, and previously limited therapeutic options. Recent breakthroughs in neuropharmacology and precision medicine have dramatically advanced treatment paradigms, ushering in targeted medications that alter disease progression, alleviate symptoms, and improve patient quality of life. This review systematically examines recent pharmacological innovations across Alzheimer's disease, Parkinson's disease (PD), and multiple sclerosis (MS). For AD, landmark disease-modifying therapies such as aducanumab and lecanemab targeting amyloid pathology, and the introduction of transdermal donepezil, have expanded therapeutic possibilities. In PD, novel formulations like opicapone and sublingual apomorphine provide enhanced control of motor fluctuations. For MS, oral sphingosine-1-phosphate receptor modulators (ozanimod, ponesimod), home-administered B-cell therapies (ofatumumab), novel fumarate formulations (monomethyl fumarate), and optimized monoclonal antibodies (ublituximab) represent significant therapeutic advancements. This review provides clinicians and researchers comprehensive, structured insights into these novel pharmacotherapies, highlighting their clinical efficacy, dosing considerations, and safety profiles, thereby facilitating informed clinical decision-making and promoting precision medicine in neurology.
References
Feigin VL, Vos T, Nichols E, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020;19(3):255-265. doi:10.1016/S1474-4422(19)30411-9
Anichini A, Salvioni Chiabotti P, Bally J, et al. Neurologie [Recent advances in neurology]. Rev Med Suisse. 2021;17(723):196-200.
Awuah WA, Ahluwalia A, Darko K, et al. Bridging Minds and Machines: The Recent Advances of Brain-Computer Interfaces in Neurological and Neurosurgical Applications. World Neurosurg. 2024;189:138-153. doi:10.1016/j.wneu.2024.05.104
Dhillon S. Aducanumab: First Approval. Drugs. 2021;81(12):1437-1443. doi:10.1007/s40265-021-01569-z
Tampi RR, Forester BP, Agronin M. Aducanumab: evidence from clinical trial data and controversies. Drugs Context. 2021;10:2021-7-3. Published 2021 Oct 4. doi:10.7573/dic.2021-7-3
U.S. Food and Drug Administration. Drug Trials Snapshots: ADUHELM. Published July 7, 2021. Accessed June 5, 2025. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-aduhelm
Sotoudeh H, Alizadeh M, Shahidi R, et al. Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy. Front Radiol. 2024;3:1305390. Published 2024 Jan 5. doi:10.3389/fradi.2023.1305390
Cummings J. Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics. Drugs. 2023;83(7):569-576. doi:10.1007/s40265-023-01858-9
Chen C, Katayama S, Lee JH, et al. Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease. J Prev Alzheimers Dis. 2025;12(5):100160. doi:10.1016/j.tjpad.2025.100160
Honig LS, Sabbagh MN, van Dyck CH, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. Alzheimers Res Ther. 2024;16(1):105. Published 2024 May 10. doi:10.1186/s13195-024-01441-8
Sozio P, Cerasa LS, Marinelli L, Di Stefano A. Transdermal donepezil on the treatment of Alzheimer's disease. Neuropsychiatr Dis Treat. 2012;8:361-368. doi:10.2147/NDT.S16089
Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L. Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther. 2024;9(1):211. Published 2024 Aug 23. doi:10.1038/s41392-024-01911-3
Berger AA, Winnick A, Izygon J, et al. Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson's Disease "Off" Episodes. Health Psychol Res. 2022;10(3):36074. Published 2022 Jun 28. doi:10.52965/001c.36074
Berger AA, Robinson C, Winnick A, et al. Opicapone for the Treatment of Parkinson's Disease "Off" Episodes: Pharmacology and Clinical Considerations. Clin Drug Investig. 2022;42(2):127-135. doi:10.1007/s40261-021-01109-3
Martinez-Nunez AE, LeWitt PA. Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson's Disease. J Parkinsons Dis. 2023;13(4):441-451. doi:10.3233/JPD-230055
Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs. 2019;33(9):905-918. doi:10.1007/s40263-019-00661-z
Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19(2):135-144. doi:10.1016/S1474-4422(19)30396-5
Lamb YN. Ozanimod: First Approval. Drugs. 2020;80(8):841-848. doi:10.1007/s40265-020-01319-7
Koscielny V. Phase III SUNBEAM and RADIANCE PART B trials for Ozanimod in relapsing multiple sclerosis demonstrate superiority versus interferon-β-1a (Avonex®) in reducing annualized relapse rates and MRI brain lesions. Neurodegener Dis Manag. 2018;8(3):141-142. doi:10.2217/nmt-2018-0012
Dumitrescu L, Papathanasiou A, Coclitu C, et al. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opin Pharmacother. 2023;24(4):495-509. doi:10.1080/14656566.2023.2178898
Kihara Y, Jonnalagadda D, Zhu Y, et al. Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P1 -selective modulation. FASEB J. 2022;36(2):e22132. doi:10.1096/fj.202101531R
Kappos L, Fox RJ, Burcklen M, et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol. 2021;78(5):558-567. doi:10.1001/jamaneurol.2021.0405
Roy R, Alotaibi AA, Freedman MS. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. CNS Drugs. 2021;35(4):385-402. doi:10.1007/s40263-021-00798-w
Hauser SL, Kappos L, Bar-Or A, et al. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment. Neurol Ther. 2023;12(5):1491-1515. doi:10.1007/s40120-023-00518-0
Kang C, Blair HA. Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis. Drugs. 2022;82(1):55-62. doi:10.1007/s40265-021-01650-7
Gärtner J, Hauser SL, Bar-Or A, et al. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Mult Scler. 2022;28(10):1562-1575. doi:10.1177/13524585221078825
Berger AA, Sottosanti ER, Winnick A, et al. Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS). Neurol Int. 2021;13(2):207-223. Published 2021 May 19. doi:10.3390/neurolint13020022
Kaye AD, Lacey J, Le V, et al. The Evolving Role of Monomethyl Fumarate Treatment as Pharmacotherapy for Relapsing-Remitting Multiple Sclerosis. Cureus. 2024;16(4):e57714. Published 2024 Apr 6. doi:10.7759/cureus.57714
Lee A. Ublituximab: First Approval. Drugs. 2023;83(5):455-459. doi:10.1007/s40265-023-01854-z
Azhar A, Taimuri MA, Shamat SF, et al. Briumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review. Ann Med Surg (Lond). 2023;85(10):4909-4912. Published 2023 Aug 16. doi:10.1097/MS9.0000000000001184
the ULTIMATE I & II Phase III trials, ublituximab (given every 6 months IV) was superior to teriflunomide, cutting annual relapses by ~60% (ARR ~0.08 on ublituximab vs 0.19 on teriflunomide)
Steinman L, Fox E, Hartung HP, et al. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2022;387(8):704-714. doi:10.1056/NEJMoa2201904
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Songül Turğut; İskender Samet Dalbatan
This work is licensed under a Creative Commons Attribution 4.0 International License.
The journal is licensed under a 